Personalized tacrolimus dosing for children after kidney transplant
Part of Kidney & urinary clinical trials.
This study tests a personalized approach to dosing tacrolimus (an anti-rejection medicine) in children who have had a kidney transplant. By using each child's own data, doctors hope to find the best dose to keep the transplanted kidney healthy and avoid side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- The patient is under 18 years old.
- This is their first kidney transplant, and they have low immune activity against donor kidneys (PRA below 20% and no donor-specific antibodies).
- They have taken their anti-rejection medicine (tacrolimus) consistently for at least a year after the transplant.
- All their medical records, including drug level blood tests, are available.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well tacrolimus, a medicine that prevents kidney rejection, works in people after a kidney transplant. By checking your immune system and your medicine levels, the goal is to find the best dose for each person to keep your new kidney healthy.
This trial tests a new way to personalize tacrolimus dosing for children after a kidney, liver, or heart transplant. It uses genetic information and a formula to find the best starting dose, aiming to improve outcomes.
This study looks at how tacrolimus (a rejection-preventing medicine) should be dosed in the first days to years after a kidney transplant. It may help personalize dosing by comparing different patient groups, including using genetic testing.
This study tests a personalized approach to managing immunosuppression after a kidney transplant to improve long-term kidney function. It may help find the right dose of tacrolimus for each person.
This study tests whether giving tacrolimus at a time of day matched to each patient's body clock can improve safety and effectiveness after a kidney transplant. It may help recipients maintain stable drug levels with fewer side effects.
This trial tests whether safely lowering the dose of tacrolimus—an anti-rejection drug—can still protect a kidney transplant one year after surgery. It's for first-time transplant recipients with low immune risk.
Hear when a new Pediatric Kidney Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.